When Lobbying Turns: Lessons From The Gun Control Debate For Pharma
The sudden shift in the politics of gun control is the latest example of how a long record of lobbying success can turn quickly.
You may also be interested in...
The Budget Blindside: Did Pharma Fight The Wrong Battle?
The bigger 'Donut Hole' discount is a rare loss for pharma on Capitol Hill – one that may in part be because industry did too good a job fighting off a different drug pricing measure.
Single Product, Single Price: Medicare Will Include All Versions Of Active Ingredient For Negotiation
The US Medicare agency intends to treat all dosage forms of the same active ingredient as a single drug for purposes of its new price negotiation authority. The approach will have implications for product branding and line extension strategies.
QALY Control: House Bill Would Ban Cost-Effectiveness Tool In US Programs
No one seems eager to defend the QALY tool as a House Republican bill seeks to prohibit any federal agency from using Quality Adjusted Life Years as a formula to determine pricing.